New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 22, 2014
06:32 EDTNUVANuVasive upgraded to Outperform from Market Perform at Leerink
Leerink upgraded NuVasive citing the company's improved operational performance and upside to consensus estimates. The firm raised its price target for shares to $45 from $33.
News For NUVA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 21, 2014
08:15 EDTNUVANuVasive price target raised to $48 from $44 at Summer Street
Subscribe for More Information
November 17, 2014
10:02 EDTNUVAOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: CyrusOne (CONE) upgraded to Buy from Hold at Stifel... MGIC Investment (MTG) upgraded to Conviction Buy from Buy at Goldman... NuVasive (NUVA) upgraded to Outperform from Market Perform at Wells Fargo... Phillips 66 (PSX) upgraded to Outperform from Neutral at Credit Suisse... Pinnacle Foods (PF) upgraded to Buy from Hold at Deutsche Bank... Rayonier (RYN) upgraded to Outperform from Sector Perform at RBC Capital.. Thoratec (THOR) upgraded to Outperform from Market Perform at Wells Fargo... Volcano (VOLC) upgraded to Outperform from Neutral at Credit Suisse... Progressive Waste (BIN) upgraded to Neutral from Underperform at Macquarie... Clean Harbors (CLH) upgraded to Outperform from Neutral at Wedbush... McGraw Hill Financial (MHFI) upgraded to Buy from Hold at Benchmark Co... Chesapeake (CHK) upgraded to Outperform from Market Perform at Bernstein... American Science & Engineering (ASEI) upgraded to Fair Value from Sell at CRT Capital... Sony (SNE) upgraded to Overweight from Equal Weight at Morgan Stanley.
05:39 EDTNUVANuVasive upgraded to Outperform from Market Perform at Wells Fargo
Wells Fargo upgraded NuVasive to Outperform after attending last week's North American Spine Society annual meeting. Wells believes the worldwide spine market continues to improve and that NuVasive is well positioned to capitalize on the momentum. The firm raised its price target range for shares to $50-$52 from $43-$44.
November 14, 2014
08:59 EDTNUVANuVasive price target raised to $51 from $49 at Canaccord
Subscribe for More Information
November 12, 2014
07:27 EDTNUVANorth American Spine Society to hold annual meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use